The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Diabetes Mellitus, Type 1
In brief
The goal of this research is to see if pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas and that works to control the amount of glucose that the liver makes, will reduce the amount of insulin required for people who must take insulin to maintain their normal blood glucose level.
Key facts
- Study ID
- NCT00791076
- Run by
- Johns Hopkins University
- People needed
- 8
- Starts
- 2007-10-01
- Expected to finish
- 2010-06-01
- Last updated by the study team
- 2017-07-12
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male and female volunteers between the ages of 18-75 with:
- 10 subjects who are status post pancreatic resection and 10 volunteers who are Type 1 diabetic for > 8 years (volunteers must have a stable glycemic profile that includes use of an insulin pump to control their blood glucose) with or without prior pancreatic resection.
- HbA1c levels ≤ 8.5.
You may not qualify if…
- Lactating or pregnant females.
- Brittle or Labile diabetics: Volunteers with extremely erratic patterns of glucose control with large fluctuations in glucose levels for no obvious reason.
- Allergy to beef or beef by-products.
- Hypoglycemia within the past year requiring medical or other assistance to correct.
- Known autonomic neuropathy.
- Documented blood glucose under 60 mg within the past year and hypoglycemic unawareness.
- Durations of type 1 Diabetes Melitis (DM) ≤ 8 years.
- Not currently on pump therapy.
- Type 1 DM who has a BMI ≥ 35.
Where it is running
- Johns Hopkins Bayview Medical Center — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.